Tenon Medical Shares Jump After FDA Clears Joint Drug for Broader Use

Dow Jones03-25

By Katherine Hamilton

Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment.

Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months.

The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.

"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market," Chief Technology Officer and co-founder Ricahrd Ginn said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 25, 2025 11:59 ET (15:59 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522003004?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-25 23:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522003004","market":"fut","top_or_hot":-1,"title":"Tenon Medical Shares Jump After FDA Clears Joint Drug for Broader Use","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment. \n</p>\n<p>\n  Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months. \n</p>\n<p>\n  The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. \n</p>\n<p>\n  \"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market,\" Chief Technology Officer and co-founder Ricahrd Ginn said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:59 ET (15:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenon Medical Shares Jump After FDA Clears Joint Drug for Broader Use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenon Medical Shares Jump After FDA Clears Joint Drug for Broader Use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-25 23:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment. \n</p>\n<p>\n  Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months. \n</p>\n<p>\n  The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. \n</p>\n<p>\n  \"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market,\" Chief Technology Officer and co-founder Ricahrd Ginn said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:59 ET (15:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522003004","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522003004","pubTimestamp":1742918340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment.Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months.The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.\"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market,\" Chief Technology Officer and co-founder Ricahrd Ginn said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","TNON":"Tenon Medical, Inc.","BK4082":"医疗保健设备","JYNT":"The Joint Corp."},"translate_title":"FDA批准联合药物更广泛使用后，Tenon Medical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1,"TNON":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment. \n\n\n  Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months. \n\n\n  The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. \n\n\n  \"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market,\" Chief Technology Officer and co-founder Ricahrd Ginn said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 11:59 ET (15:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522003004"}